ArticleFrontiers in medicine2025
Treatment of metastatic bladder paraganglioma with cadonilimab plus radiotherapy: a case report and literature review.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder paraganglioma (PPGL) is a rare neuroendocrine tumor associated with a lower survival rate compared to paragangliomas originating in other anatomical locations. Surgical resection is still the primary treatment modality for bladder paraganglioma; however, this approach carries a significant risk of malignant metastasis. Once metastasis occurs, therapeutic options become notably limited. The response rate and 5-year overall survival for bladder paraganglioma treated with cyclophosphamide, vincristine, and dacarbazine (CVD) chemotherapy are relatively low. Recent advancements in tumor immunotherapy, particularly antibodies targeting CTLA-4 and PD-1/PD-L1, have effectively treated various cancers, including neuroendocrine tumors. These immunotherapeutic approaches offer promising alternatives and potentially improve outcomes for patients with metastatic bladder paraganglioma. Case description: A 44-year-old male presented with intermittent hematuria, abdominal pain, and frequent urination. Pre-operative computed tomography (CT) revealed a neuroendocrine tumor and a laparoscopic partial cystectomy was subsequently performed. Post-operative pathology confirmed paraganglioma of the bladder, with immunohistochemical results showing SYN (+), P504S (+/-), and Ki-67 (+20%). The patient's post-operative symptoms resolved, returning to normal. However, recurrence occurred 33 months post-surgery. The patient later received 11 cycles of cadonilimab and local radiation therapy, with tumor progression evaluated via imaging every 2 months. During the follow-up period, the patient maintained stable disease for 12 months. After local progression, the patient received targeted therapy, chemotherapy, and palliative treatment. Survival time after recurrence is 25 months. Overall survival from diagnosis is 58 months. Conclusions: We report, for the first time, a case of metastatic bladder paraganglioma in which a patient treated with cadonilimab in combination with radiotherapy maintained stable disease for 12 months. These results demonstrate that this combination therapy may be a potential treatment option for bladder paraganglioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.